P62 as a diagnostic tool for alzheimer's disease

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007100, C435S007900, C435S007920, C436S503000, C436S501000

Reexamination Certificate

active

07608412

ABSTRACT:
The p62 protein has been analyzed and identified as the significant contributor to several metabolic pathways that lead to metabolic syndrome, Alzheimer's Disease, and other related diseases. The absence of the p62 protein has a profound effect on the accumulation of tau protein, amyloid beta protein and an increase in blood insulin levels. The accumulation of tau protein and amyloid beta protein in neurological tissues is a hallmark of neurological metabolic diseases such as Alzheimer's Disease and related dementias. Moreover, increase blood insulin levels is an indicator of insulin resistance in mammals. Accordingly, the present invention provides a method for screening a mammal for metabolic disease comprising the step of detecting the absence of the p62 protein. The present invention also contemplates a method of screening a mammal for a metabolic syndrome comprising the steps of detecting the level of p62 protein in a metabolic pathway and determining whether the level of p62 protein falls below a threshold level. A pharmaceutical composition is also contemplated for therapeutic supplementation of a metabolic pathway, the pharmaceutical composition comprising a p62 protein or an amide, ester or salt thereof and a pharmaceutically effective carrier. Such pharmaceutical composition will have an inhibitory action on the phosphorylation, ubiquitination, accumulation of tau protein, an inhibitory effect on the accumulation of APP/amyloid beta and may operate to lower blood insulin levels.

REFERENCES:
patent: WO 97/22255 (1997-06-01), None
patent: WO 2005/050170 (2005-06-01), None
Schenk et al., 1995, J. Med. Chem., vol. 38, No. 21, pp. 4141-4154.
Database Biosis [Online] Biosciences Information Service, Philadelphia, PA US; 2003, C.Y. Shao et al. “Association of PKCiota/lambda, p62 and ubiquitin with inclusions of neurodegenerative disease.”
E. Kuusisto et al. “Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: Possible role in tangle formation,” Neuropathology and Applied Neurobiology, vol. 28, No. 3, Jun. 2002, pp. 228-238.
K. Zatloukal et al. “P62 is a common component of cytoplasmic inclusions in protein aggregation diseases,” American Journal of Pathology, Philadelphia, PA, vol. 160, No. 1, Jan. 2002 pp. 255-263.
E. Kuusisto et al. “Ubiquitin-binding protein P62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies,” Neuroreport Rapid Communications of Oxford, Oxford, Great Britain, vol. 12, No. 10, Jul. 20, 2001, pp. 2085-2090.
Carolin Lackner et al. “p62 protein is expressed in pancreatic beta cells” Journal of Pathology, vol. 206, No. 4, Aug. 2002(Aug. 2005), pp. 402-408.
H. Lage et al. “Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation,” Virchows Archive, Springer International, Berlin, DE, vol. 438, No. 6, Feb. 21, 2001, pp. 567-573.
Nagaoka Utako at al. “Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions” Journal of Neurochemistry, vol. 91, No. 1, Oct. 2004, pp. 57-68.
Nakano Toshiya et al. “Expression of ubiquitin-binding protein p62 in ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral sclerosis with dementia: analysis of five autopsy cases with broad clinicopathological spectrum,” Acta Neuropathologica Apr. 2004, vol. 107, No. 4, Apr. 2004, pp. 359-364.
Angelina Rodriguez, et al. “Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62” Cell Metabolism, vol. 3, No. 3, Mar. 2006, pp. 211-222.
Andorfer, C, and Y. Kress, et al. (2003)Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. . Neurochem. 86, 582-590.
Babu, J., T. Geetha, & M. Wooten (2005)Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J. Neurochem. 94, 192-203.
Bennett, E.M., N.P. Bence, et al. (2005)Global Impairment of the ubiquitin proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol. Cell 17, 351-365.
Busciglio, J., A. Lorenzo, et al. (1995)Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14, 879-888.
Capsoni, S., G. Comparini, et al. (2000)Alzheimer-like neurodegeneration in aged anti-nerve growth factor transgenic mice. Proc. Natl. Acad. Sci. USA 97, 6826-6831.
Chang, S., J.H. Kim, & J. Shin, (2002)P62 forms a ternary complex with PKCC and PAR-4 and antagonizes PAR-4 induced PKCC inhibition. FEBS Lett. 510, 57-61.
Dou, F., W. Netzer, et al. (2003)Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. USA 2, 721-726.
Duran, A., M. Serrano, et al. (2004)The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogensis. Dev. Cell 6, 303-309.
Etlene-Mannerville, S. & A. Hall, (2003)CDC42 regulates GSK3β and adenomatous polyposis coli to control cell polarity. Nature 421, 753-756.
Gallyas, F., (1971)Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung 19, 1-8.
Greetha, T. & M.W. Wooten, (2003)Association of the atypical protein kinase C-interacting protein p62/ZIP with nerve growth factor TrkA regulates receptor trafficking and Erk5 signaling. J. Biol. Chem. 278, 4730-4739.
Gerber, S., J. Rush, et al. (2003)Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. USA 100, 6940-6945.
Godermann, R., J. Biernat, E.Mandelkow (1999)Phosphorylation of tau proteins by recombinant GSK3β: pronounced phosphorylation at select Ser/Thr-Pro motifs but no phosphorylation at Ser 262 in the repeat domain. FEBS Lett. 454, 157-164.
Gotz, J., F. Chen, J. van Dorpe & R. M. Nitsch. (2001)Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ42 fibrils. Science 293, 1491-1495.
Gotz, J., F. Chen, et al. (2001)Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276, 529-534.
Greenburg, S.G. & P.A. Davis, (1990)A preparation of Alzheimer paried helical filaments that displays distinct τ proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. USA 87, 5827-5831.
Guntern, R., C. Bouras, P.R. Hoff & P.G. Vallet, (1992)An improved thioflavine-S method for staining neurofibrillary tangles and sensile plaques in Alzheimer's disease. Experientia. 48, 8-10.
King, G.D. & R.S. Turner, (2004)Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk? Exp. Neurol. 185, 208-219.
Lione, L.A., R.J. Carter, et al. (1999)Selective discrimination learning impairments to mice expressing the human Huntington's disease mutation. J.Neurosci. 19, 10428-10437.
Li, B., R. Ryder, et al., (2004)Overexpression of GSK3BS9A resulted in tau hyperphosphorylation and morphology reminiscent of pretangle-like neurons in the brain of PDGSK3β transgenic mice. Transgenic Res. 13, 385-396.
Oddo, S., A. Caccamo, et al. (2003)Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39, 409-421.
Peng, J., D. Schwartz, et al. (2003)A proteomics approach to understanding protein ubiquitination. Nat. Biotechnol. 21, 921-926.
Peng, J., M.J. Kim, et al. (2004)Semiquantitative proteomic analysis of rat forebrain postsynaptic density fractions by mass spectrometry. J. Biol. Chem. 279, 21003-21011.
Porter, V.R., W. Buxton, et al. (2003)Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias. J. Neuropsychiatry Clin. Neurosci. 15, 180-186.
Puls, A., S. Schmidt, F. Grawe & S. Stabel (1997)Interation of protein kinase C zeta with ZIP, a novel protein kinase C-binding protein. Proc. Natl. Acad. Sci. USA 94, 6191-6196.
Rankin, C.A., Q. S

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

P62 as a diagnostic tool for alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with P62 as a diagnostic tool for alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P62 as a diagnostic tool for alzheimer's disease will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4118535

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.